Evidence map›Paper›PMID 33515132›Full record

ArticleAIDS and behavior2021

Multilevel Barriers to HIV PrEP Uptake and Adherence Among Black and Hispanic/Latinx Transgender Women in Southern California.

Adedotun Ogunbajo, Erik D Storholm, Allison J Ober, Laura M Bogart, Cathy J Reback, Risa Flynn, Phoebe Lyman, Sheldon Morris

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in AIDS and behavior, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06159582 (eSTEP), which is not on this map. Cited by 86 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 2 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06159582 nacompletednot on this mapstarted 2024, after this paper: background citation

eSTEP: An Integrated mHealth Intervention to Engage High-risk Individuals Along the Full PrEP Care Continuum

TypeinterventionalSponsorSan Diego State UniversityRan2024 to 2025Enrolled113ConditionsPre-Exposure Prophylaxis (PrEP)ArmseSTEP, Usual Care
3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 2 syntheses or guidelines pooled it, 143 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Adedotun OgunbajoDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. dotunogunbajo@gmail.com.ORCID http://orcid.org/0000-0002-3074-6431
Erik D StorholmSchool of Public Health, San Diego State University, San Diego, CA, USA.
Allison J OberRAND Corporation, Santa Monica, CA, USA.
Laura M BogartRAND Corporation, Santa Monica, CA, USA.
Cathy J RebackDepartment of Family Medicine, Center for HIV Identification, Prevention and Treatment Services, University of California Los Angeles, Los Angeles, CA, USA.
Risa FlynnLos Angeles LGBT Center, Los Angeles, CA, USA.
Phoebe LymanLos Angeles LGBT Center, Los Angeles, CA, USA.
Sheldon MorrisAntiViral Research Center, San Diego School of Medicine, University of California, San Diego, CA, USA.
RAND Corporation · USLos Angeles LGBT Center · USHarvard University · USUniversity of California, Los Angeles · USUniversity of California San Diego · US

Funding

UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAPHAEL J LANDOVITZ · 1997 to 2026
$53.5M
Risk and Protective Factors for Adherence to Pre-Exposure Prophylaxis (PrEP) in Transwomen of ColorR21DA044073 · NIDA · RAND CORPORATION · PI STORHOLM, ERIK D. · 2017 to 2018
$494k
Developing a PrEP Screening Instrument for Identification/Referral of High-Risk MSM in Primary CareR03DA043402 · NIDA · RAND CORPORATION · PI STORHOLM, ERIK D. · 2017 to 2018
$345k
California HIV/AIDS Research Program PR15-SD-021NIDA NIH HHS DA043402NIDA NIH HHS DA044073NIDA NIH HHS R03 DA043402NIDA NIH HHS R21 DA044073NIMH NIH HHS MH58107NIMH NIH HHS P30 MH058107
6 · The paper itself

Abstract

Black and Hispanic/Latinx transgender women in the United States (U.S.) are disproportionately affected by HIV. Pre-exposure prophylaxis (PrEP) reduces risk of HIV infection but PrEP uptake remains low among Black and Hispanic/Latinx transgender women. Between July 2018 and August 2019, we conducted individual interviews with 30 Black and Hispanic/Latinx transgender women who were prescribed PrEP through a PrEP demonstration project and 10 healthcare providers who provide PrEP services to transgender women in Los Angeles and San Diego, California. The interviews assessed general attitudes, experiences, and beliefs about PrEP as well as individual-, interpersonal-, community-, and structural-level barriers to PrEP uptake and adherence. PrEP adherence was assessed by collecting quantitative intracellular tenofovir-diphosphate (TFV-DP) levels in retrospect on batched, banked dried blood spot (DBS) samples. We utilized qualitative content analysis to identify themes from the interviews. Findings indicated the presence of individual-level barriers including cost concerns, mental health issues, substance use, and concerns about PrEP side effects including hormone interaction. Interpersonal-level barriers included the influence of intimate/romantic partners and the impact of patient-provider communication. Community-level barriers consisted of experiencing stigma and negative community opinions about PrEP use as well as having negative experiences in healthcare settings. Structural-level barriers included unreliable transportation, employment, and housing insecurity. Interventions aiming to increase PrEP uptake and adherence among Black and Hispanic/Latinx transgender women in the U.S. should employ a multilevel approach to addressing the needs of transgender women, especially the structural barriers that have greatly limited the use of PrEP.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisTransgender PersonsBlack or African AmericanFemaleHispanic or LatinoHumansLos AngelesMaleUnited StatesAnti-HIV AgentsBlackHispanic/LatinxHIV preventionPrEP adherenceTransgender women

Identifiers

PMID33515132
PMCPMC7845787
OpenAlexW3122416898

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.